New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 29, 2013
11:34 EDTIDRAIdera deal with NCI a positive surprise, says Piper Jaffray
Piper Jaffray views Idera's agreement with the National Cancer Institute to study TLR antagonists in lymphoma as a positive surprise and sees the potential for shares to trade higher. Piper reiterates its Overweight rating and $2.60 target on Idera.
News For IDRA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 14, 2014
08:19 EDTIDRAIdera Pharmaceuticals advanced IMO-9200 into Phase 1 clinical development
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use